PMC4860976_01
Wound dehiscence and scleral exposure in the first patient, 10 days after Ahmed Glaucoma Valve implantation with adjunctive subconjunctival bevacizumab.
JOVR-11-112-g001.jpg
PMC4860976_01_JOVR-11-112-g001.jpg
F1
On day 3 after admission, anterior migration of the tube and complete wound dehiscence was observed [Figures 1 and 2].
Tube migration after Ahmed Glaucoma Valve implantation with adjunctive subconjunctival bevacizumab in the first patient.
JOVR-11-112-g002.jpg
PMC4860976_01_JOVR-11-112-g002.jpg
F2
On day 3 after admission, anterior migration of the tube and complete wound dehiscence was observed [Figures 1 and 2].
PMC4860976_02
Plate exposure in the second patient 5 months after Ahmed Glaucoma Valve implantation with adjunctive subconjunctival bevacizumab.
JOVR-11-112-g003.jpg
PMC4860976_02_JOVR-11-112-g003.jpg
F3
During repeat surgery, migration of the AGV and melting of the scleral patch graft were observed [Figure 3].